| Name | Title | Contact Details |
|---|
We firmly believe in the integration of science research and traditional wisdom as the way that nutritional and herbal supplements will reach their exciting potential. Founded in 1990 by a pioneering physician committed to science-based alternative health care, Doctor’s Best offers only the most important nutritional supplements. Careful research and precise formula development keeps us at the leading edge of quality, effectiveness, and innovation. Containing the finest quality raw materials from around the world, Doctor’s Best supplements embody the best that traditional knowledge and current scientific research have to offer in the field of therapeutic nutrition. Countless hours have been spent analyzing scientific literature to provide sound alternatives to the proliferation of questionable supplements in the marketplace. Each of our products is accompanied by an annotated ""Fact Sheet"" with detailed background information, structure-function statements, and scientific references that substantiate these statements. All structure-function statements have been filed with FDA in accordance with DSHEA regulations.
Aquascience Research Group is a Kansas City, MO-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Pandion Therapeutics is a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation at the site of disease for durable, tissue-specific treatment of patients with autoimmune and inflammatory disease and organ transplants.
Disc Medicine is a clinical-stage biopharmaceutical company that is dedicated to transforming the lives of patients with hematologic disorders. We are building a portfolio of innovative, first-in-class therapeutic candidates that affect fundamental pathways of red blood cell biology. Disc Medicine is committed to developing treatments that empower and bring hope to the many patients who suffer from hematologic disease.
CytoDyn is a biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies for the treatment and prevention of Human Immunodeficiency Virus (HIV) infection. We have one of the leading monoclonal antibodies under development for HIV infection, PRO 140, which prevents viral entry into healthy T-cells by blocking the HIV co-receptor CCR5. The drug candidate is also being tested for other immunological conditions, and has been granted FDA orphan drug status for the treatment of Graft versus Host Disease (GvHD) in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who are undergoing bone marrow stem cell transplantation.